139 related articles for article (PubMed ID: 33051796)
1. Enhancer of Zeste Homolog 2 (EZH2) in Malignant Progression of Gallbladder Carcinoma.
Behera G; Mitra S; Mishra TS; Purkait S
J Gastrointest Cancer; 2021 Sep; 52(3):1029-1034. PubMed ID: 33051796
[TBL] [Abstract][Full Text] [Related]
2. Elevated Expression of DNA Methyltransferases and Enhancer of Zeste Homolog 2 in Helicobacter pylori - Gastritis and Gastric Carcinoma.
Purkait S; Patra S; Mitra S; Behera MM; Panigrahi MK; Kumar P; Kar M; Hallur V; Chandra Samal S
Dig Dis; 2022; 40(2):156-167. PubMed ID: 33895728
[TBL] [Abstract][Full Text] [Related]
3. Altered expression of epigenetic modifiers EZH2, H3K27me3, and DNA methyltransferases in meningiomas - prognostic biomarkers for routine practice.
Samal S; Patnaik A; Sahu F; Purkait S
Folia Neuropathol; 2020; 58(2):133-142. PubMed ID: 32729292
[TBL] [Abstract][Full Text] [Related]
4. [Expression of enhancer of zesle homolog 2 and phosphatase and tension homolog and its clinicopathological significance in benign and malignant lesion of gallbladder].
Liu DC; Yang ZL; Yang LP
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Jul; 33(7):618-22. PubMed ID: 18667776
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma.
Liu DC; Yang ZL
Pathol Res Pract; 2011 Aug; 207(8):472-8. PubMed ID: 21719208
[TBL] [Abstract][Full Text] [Related]
6. Long non-coding RNA MINCR promotes gallbladder cancer progression through stimulating EZH2 expression.
Wang SH; Yang Y; Wu XC; Zhang MD; Weng MZ; Zhou D; Wang JD; Quan ZW
Cancer Lett; 2016 Sep; 380(1):122-33. PubMed ID: 27345740
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
[TBL] [Abstract][Full Text] [Related]
8. Expression of EZH2 and H3K27me3 predicts tumor biology of urothelial carcinoma.
Mohamedali R; Mitra S; Mandal S; Nayak P; Adhya AK; Purkait S
Indian J Pathol Microbiol; 2023; 66(3):488-494. PubMed ID: 37530328
[TBL] [Abstract][Full Text] [Related]
9. Differential Expression of EZH2 and H3K27me3 in Oral Verrucous Carcinoma and Oral Verrucous Hyperplasia.
Sihavong P; Kitkumthorn N; Srimaneekarn N; Bumalee D; Lapthanasupkul P
Head Neck Pathol; 2021 Jun; 15(2):408-415. PubMed ID: 32720035
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic modifications in cutaneous malignant melanoma: EZH2, H3K4me2, and H3K27me3 immunohistochemical expression is enhanced at the invasion front of the tumor.
Kampilafkos P; Melachrinou M; Kefalopoulou Z; Lakoumentas J; Sotiropoulou-Bonikou G
Am J Dermatopathol; 2015 Feb; 37(2):138-44. PubMed ID: 25614949
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA UCA1 promotes gallbladder cancer progression by epigenetically repressing p21 and E-cadherin expression.
Cai Q; Jin L; Wang S; Zhou D; Wang J; Tang Z; Quan Z
Oncotarget; 2017 Jul; 8(29):47957-47968. PubMed ID: 28624787
[TBL] [Abstract][Full Text] [Related]
12. Long noncoding RNA MALAT1 potentiates growth and inhibits senescence by antagonizing ABI3BP in gallbladder cancer cells.
Lin N; Yao Z; Xu M; Chen J; Lu Y; Yuan L; Zhou S; Zou X; Xu R
J Exp Clin Cancer Res; 2019 Jun; 38(1):244. PubMed ID: 31174563
[TBL] [Abstract][Full Text] [Related]
13. EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion.
Yi X; Guo J; Guo J; Sun S; Yang P; Wang J; Li Y; Xie L; Cai J; Wang Z
Sci Rep; 2017 Jun; 7(1):3568. PubMed ID: 28620234
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic profiling of gallbladder cancer and gall stone diseases: Evaluation of role of tumour associated genes.
Singh TD; Gupta S; Shrivastav BR; Tiwari PK
Gene; 2016 Feb; 576(2 Pt 2):743-52. PubMed ID: 26456195
[TBL] [Abstract][Full Text] [Related]
15. Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients.
Liu F; Gu L; Cao Y; Fan X; Zhang F; Sang M
Biomarkers; 2016; 21(1):80-90. PubMed ID: 26631178
[TBL] [Abstract][Full Text] [Related]
16. Loss of enhancer of zeste homologue 2 (EZH2) at tumor invasion front is correlated with higher aggressiveness in colorectal cancer cells.
Böhm J; Muenzner JK; Caliskan A; Ndreshkjana B; Erlenbach-Wünsch K; Merkel S; Croner R; Rau TT; Geppert CI; Hartmann A; Roehe AV; Schneider-Stock R
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2227-2240. PubMed ID: 31317325
[TBL] [Abstract][Full Text] [Related]
17. High expression of trimethylated histone H3 at lysine 27 predicts better prognosis in non-small cell lung cancer.
Chen X; Song N; Matsumoto K; Nanashima A; Nagayasu T; Hayashi T; Ying M; Endo D; Wu Z; Koji T
Int J Oncol; 2013 Nov; 43(5):1467-80. PubMed ID: 23969945
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of promoter DNA hypermethylation of the cysteine dioxygenase 1 (CDO1) gene in primary gallbladder cancer and gallbladder disease.
Igarashi K; Yamashita K; Katoh H; Kojima K; Ooizumi Y; Nishizawa N; Nishiyama R; Kawamata H; Tajima H; Kaizu T; Kumamoto Y; Watanabe M
PLoS One; 2017; 12(11):e0188178. PubMed ID: 29161283
[TBL] [Abstract][Full Text] [Related]
19. CLDN14 is epigenetically silenced by EZH2-mediated H3K27ME3 and is a novel prognostic biomarker in hepatocellular carcinoma.
Li CP; Cai MY; Jiang LJ; Mai SJ; Chen JW; Wang FW; Liao YJ; Chen WH; Jin XH; Pei XQ; Guan XY; Zeng MS; Xie D
Carcinogenesis; 2016 Jun; 37(6):557-566. PubMed ID: 27207647
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of histone marks H3K27me3 and H3K9me3 and modifying enzymes EZH2, SETDB1 and LSD-1 in colorectal cancer.
Carvalho S; Freitas M; Antunes L; Monteiro-Reis S; Vieira-Coimbra M; Tavares A; Paulino S; Videira JF; Jerónimo C; Henrique R
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2127-2137. PubMed ID: 30105513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
